ArticleTranslational lung cancer research2020

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.

Toshimitsu Yamaoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.